Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05752175
Other study ID # WPV01-CP-02
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 10, 2023
Est. completion date July 3, 2023

Study information

Verified date June 2024
Source Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of WPV01 in patients with mild/moderate COVID-19 infection


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date July 3, 2023
Est. primary completion date May 9, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Participants =18 years of age when signing ICF; 2. Initial onset at least 1 of 11 COVID-19 symptoms within 48 hours before randomization; 3. Within three days before randomization, the RT-PCR test of specimens such as nasal and pharyngeal swabs must be positive for SARS-CoV-2 or the rapid antigen test must be positive, and also the patiets should meet the diagnostic criteria for mild or moderate cases as defined in the Diagnosis and Treatment Protocol for COVID-19 (Trial Version 10) issued by the National Health Commission of China; 4. Fertile participants must agree to take effective contraceptive measures; 5. Participants who understand and agree to comply with planned study procedures,voluntarily participate in this clinical trial and sign an informed consent form. Exclusion Criteria: 1. Known allergy to any ingredient in the study treatment drug; 2. Patients who meet the diagnostic criteria for severe or critical cases of COVID-19 as defined in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 10) issued by the National Health Commission of China at the time of randomization; 3. Obvious abnormal liver function (ALT or AST = 3ULN, or total bilirubin =1.5ULN); 4. On dialysis or combined with moderate to severe kidney injury; 5. Patients with compromised immune system; 6. Patients with acute exacerbation of chronic respiratory disease at screening, including bronchial asthma, chronic obstructive pulmonary disease; 7. Patients with suspected or confirmed concurrent active systemic infection other than COVID-19 at screening; 8. Any comorbidity requiring surgery within 14 days prior to study entry, or that is considered life threatening within 30 days prior to study entry, as determined by the investigator; 9. Has received or is expected to receive COVID-19 monoclonal antibody or convalescent COVID-19 plasma during study treatment; 10. Has received treatment with antivirals against SARS-CoV-2 within 14 days prior to randomization; 11. Has received any novel coronavirus infection vaccine within 1 week prior to randomization; 12. Current or expected use of strong CYP3A4 inducers, inhibitors or medications that are highly dependent on CYP3A4 for clearance; 13. Difficulty swallowing or a history of gastrointestinal disorders that severely interfere with drug absorption; 14. BMI=30 kg/m2; 15. Pregnant, lactating women or those with a positive pregnancy test; 16. Previous administration with any investigational drug within 3 months before the study drug administration; 17. Patients who are judged by the investigator to be unsuitable to participate in this study.

Study Design


Intervention

Drug:
WPV01
WPV01 tablets
Placebo
Placebo tablets

Locations

Country Name City State
China Shulan(Hangzhou) Hospital Hangzhou

Sponsors (1)

Lead Sponsor Collaborator
Westlake Pharmaceuticals (Hangzhou) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in viral load Change of viral load compared to the baseline Baseline through Day 7
Secondary Change in the total score of COVID-19 symptoms Change in the total score of COVID-19 symptoms compared to the baseline Baseline through Day 14
Secondary Change in the score of each COVID-19 symptom Change in the score of each COVID-19 symptom compared to the baseline Baseline through Day 14
Secondary Change of EuroQol Questionnaire - 5 Dimension (EQ-5D) Change of EuroQol Questionnaire - 5 Dimension (EQ-5D) compared to the baseline Baseline through Day 14
Secondary percentage of patients who reached the sustained clinical recovery of COVID-19 symptoms in every visit percentage of patients who reached COVID-19 symptoms scores of 0 for two consecutive days in every visit Baseline through Day 14
Secondary Time to the first negative SARS CoV-2 test result The time from the start of treatment to the time when the first negative SARS CoV-2 qPCR result showed CT value =35 Baseline through Day 14
Secondary progression of COVID-19 infection the percentage of patients who progressed to severe/critical COVID-19 or death from any cause Baseline through Day 14
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04997551 - Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19 Phase 3
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Completed NCT05049226 - Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine Phase 2
Terminated NCT04455815 - A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Completed NCT04662437 - The Status of Parathyroid Hormone Secretion in Covid-19 Patients
Recruiting NCT05792878 - Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy
Completed NCT04659200 - Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients
Recruiting NCT04470583 - Evaluating Clinical Parameters of COVID-19 in Pregnancy
Withdrawn NCT04377568 - Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children Phase 2
Completed NCT04848610 - The Factors That Affect the Infection of COVID-19
Recruiting NCT04582903 - Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Recruiting NCT06032000 - Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203) Phase 1
Terminated NCT04941703 - "CHANGE COVID-19 Severity" Phase 1/Phase 2
Active, not recruiting NCT04639466 - A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection Phase 1/Phase 2
Completed NCT04575038 - CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 Phase 2
Recruiting NCT05022446 - The Impact of COVID-19 on Pulmonary Procedures
Completed NCT04347798 - IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
Active, not recruiting NCT04650178 - Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials
Recruiting NCT04169542 - Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery